Solmedx | Immunograph Analyzer for Doctors, Bio Markers, Drug Screeners and More

Immunograph Specialists

Solmedx Clinical Studies

As we develop data on our clinical studies, we would be happy to share our results with you. If you would like to receive new data as it is generated, please Contact Us and give us your email address. We promise to send only data and no promotional material.

Current ongoing clinical studies include:

IRB PROTOCOL NO.: 0120090320 (download copy of IRB)
Principal Investigator: Zamir Brelvi, MD, PhD, University of Medicine and Dentistry New Jersey
Co-investigators: Dharmesh Kaswala, MD; Nitin Patel, MD; Andrew Morianu, MD; and Michael Demyen, MD

Download: CONSENT TO TAKE PART IN A RESEARCH STUDY. TITLE OF STUDY: Role of ROX™ and BOX™
biomarkers as monitors of Interferon Treatment response in Hepatitis C patients.

ROLE OF ROX AND BOX BIOMARKERS AS MONITORS OF INTERFERON TREATMENT IN HEPATITIS C PATIENTS

This study is currently underway to identify the non-responder for Hepatitis C treatment. Benefits include potential cost and time savings, for both physicians and patients. Early detection may help in preventing side effects from interferon during treatment. By quantifying the patient's immune system, this study identifies which patients are nonresponders to interferon/Ribavirin treatment. Additional benefits of the ROX tests for HEP C patients include:

• predicting inflammation before other tests
• determining the dose of interferon that should be required for each specific patient
• identifying alternative course of treatment for non-responders

Additional clinical studies are planned for ALS; Alzheimer's, Huntington's, MS, and other neurodegenerative diseases; Cancer, Complex Regional Pain Syndrome; Diabetes; HIV/AIDS; Parkinson's Disease; and Rheumatoid Arthritis (RA) and other auto-immune diseases.

If you are interested in taking part in a clinical study, please Contact Us.

View Dr. Sofer's presentation at The World Pharmaceutical Congress, titled: "ROX™ and BOX™: new tools for detecting patient injury and drug toxicity.

Solmedx Presentation Download Presentation

Download Technical Paper

Exciting New Developments:

	At present, clinical trials are under way with patients with Hepatitis C and a control group (University of Medicine & Dentistry of New Jersey IRB Protocol No. 0120090320). The purpose of the clinical trial is to identify patients who have an imbalanced ROX and examine their progress during the course of treatment with interferon and ribavirin supplements. By quantifying the patient's ROX delivery system, this study identifies which patients are non-responders to interferon/Ribavirin treatment.

PLANNED CLINICAL TRIALS:
	ALS: Imbalanced ROX at the motor neuron leads to oxidative damage to the motor neuron and surrounding tissue.

	Alzheimer's, Huntington's, MS, and other neurodegenerative diseases: Imbalanced ROX for nervous system leads to oxidative damage of nerve tissue and surroundings.

	Cancer: A tumor cannot be contained if there is insufficient ROX; A cancer patient with sufficient ROX can prevent a tumor from spreading by destroying any metastasized cancer cells.

	Complex Regional Pain Syndrome (CRPS): Out of balance ROX allows free radicals to cause pain.

	Diabetes: If not enough ROX is delivered for glucose to convert to energy, added insulin will not control the patient's sugar level.

	HIV/AIDS: When a T-cell recognizes a virus, it recruits a critical mass of ROX to destroy the virus. Insufficient ROX would not allow a critical mass to focus on the virus, allowing it to spread out and destroy the T-cell and surrounding tissue.

	Parkinson's Disease: If less than a critical mass of ROX exists, radicals will be released at the surrounding tissues, causing widespread damage. This can begin a chain of events leading to PD.

	Rheumatoid Arthritis (RA) and other auto-immune diseases: Insufficient ROX allows for the indiscriminate spread of radical oxygen species, thus damaging surrounding tissues.

Solmedx can be found online under the following tags:
interferon treatment, patient blood samples, ROX (reservoir oxygen capacity), Cancer, innate immune viability, AIDs, BOX, blood cell oxygen capacity,
adaptive immune system strength,proper medication dosage, clinical studies,Hepatitis C, Diabetes, patient injury and drug toxicity Alzheimer's, ALS, and other neurodegenerative diseases; Cancer; Diabetes; HIV/AIDS, Huntington's Disease, Parkinson's Disease (PD), Rheumatoid Arthritis (RA) and other auto-immune diseases; and Complex Regional Pain Syndrome (CRPS)]

Website hosting by Solution-Area.Net